Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.
Gopinath B, Musselman R, Beard N, El-Kaissi S, Tani J, Adams CL, Wall JR.
S Afr Med J. 2015 Oct;105(10):875. doi: 10.7196/samjnew.8768.
PMID:26636154
Treatment of thyroid ocular myopathy with adjustable and nonadjustable suture strabismus surgery.
Kraus DJ, Bullock JD.
Trans Am Ophthalmol Soc. 1993;91:67-79; discussion 79-84.
PMID:8140707
Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete alpha (CXCL10) and beta (CCL2) chemokines under the influence of cytokines that are modulated by PPARgamma.
Antonelli A, Ferrari SM, Corrado A, Franceschini SS, Gelmini S, Ferrannini E, Fallahi P.
Autoimmun Rev. 2014 Nov;13(11):1160-6. doi: 10.1016/j.autrev.2014.08.025. Epub 2014 Aug 27.
PMID:25172242
Thyrotoxic Myopathy with Nonspecific Ophthalmopathy in a Two-Year-Old Child: Case Report and Literature Review.
Smółka K, Perenc L, Pelc J, Smółka L, Szajnik K.
J Clin Med. 2024 Oct 17;13(20):6180. doi: 10.3390/jcm13206180.
PMID:39458129
Clinical and imaging clues to the diagnosis and follow-up of ptosis and ophthalmoparesis.
Keene KR, Kan HE, van der Meeren S, Verbist BM, Tannemaat MR, Beenakker JM, Verschuuren JJGM.
Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism.
Gunji K, De Bellis A, Li AW, Yamada M, Kubota S, Ackrell B, Wengrowicz S, Bellastella A, Bizzarro A, Sinisi A, Wall JR.